Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Randomized controlled trials (RCTs) continue to be the basis for essential evidence regarding the efficacy of interventions such as cancer therapies. Limitations associated with RCT designs, including selective study populations, strict treatment regimens, and being time-limited, mean they do not provide complete information about an intervention’s safety or the applicability of the trial’s results to a wider range of patients seen in real-world clinical practice. For example, recent data from Alberta showed that almost 40% of patients in the province’s cancer registry would be trial-ineligible per common exclusion criteria. Real-world evidence (RWE) offers an opportunity to complement the RCT evidence base with this kind of information about safety and about use in wider patient populations. It is also increasingly recognized for being able to provide information about an intervention’s effectiveness and is considered by regulators as an important component of the evidence base in drug approvals. Here, we examine the limitations of RCTs in oncology research, review the different types of RWE available in this area, and discuss the strengths and limitations of RWE for complementing RCT oncology data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These observational studies are at moderate to high risk of bias and have several limitations that hinder causal inference, including lack of randomization and reliance on medical claims and medical record documentation for the evaluation of exposure (e.g.,. GLP-1 RA use) and outcomes (e.g., thyroid cancer and subtypes).50”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Observational studies using data generated as part of clinical practice can provide real-world evidence of effectiveness and safety. Yet, they are prone to confounding and biases that hinder causal inference, in this case, supporting a causal association between GLP-1 RA use and development or diagnosis of thyroid cancer.49,50”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., & Johnston, J. (2015) · Trials · doi:10.1186/s13063-015-1023-4 · Cited by 878
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739
Desai, R. J., & Franklin, J. M. (2019) · BMJ · doi:10.1136/bmj.l5657 · Cited by 657
Amir, E., Seruga, B., Niraula, S., Carlsson, L., & Ocaña, A. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr242 · Cited by 622
Research works printed but not linked: 1
- Setoguchi, 2013, Chapter 5: comparator selection.
Cited by
ESMO guidance for reporting oncology real-world evidence (GROW)
Castelo-Branco, L., Pellat, A., Martins-Branco, D., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.001 · Cited by 247
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
Castelo-Branco, L., Pellat, A., Martins-Branco, D. A., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U. G., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2023.10.001 · Cited by 40
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
“49,50 T h e l ea v e on e - ou t a n a l y s i s s ho w e d t h a t t h e e x c l u s i on o f non e o f t h e i n c l ud e d s t ud i e s m od i fi e d t h e e x t e n t o f t h e e ff ec t , bu t l ea v e ou t o f fi v e s t ud i e s w e r e i d e n ti fi e d w ho s e e x c l u s i on w ou l d l ea…”
stefanolo, J. P., Segura, V., Grizzuti, M., Heredia, A., Comino, I., Costa, A. F., Puebla, R. A., Temprano, M. P., Niveloni, S. I., de Diego, G. A., et al. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i11.1545 · Cited by 32
“Consequently, the enforced stay-at-home measures during this time may have contributed to improved adherence to the GFD, as has been suggested by a recent study[31].”
Gandaglia, G., Pellegrino, F., Golozar, A., Meulder, B. D., Abbott, T., Achtman, A. H., Omar, M. I., Alshammari, T. M., Areia, C. M., Asiimwe, A., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.06.012 · Cited by 20
“Therefore, these might be less generalizable at a population level, where 40% of cancer patients would be eligible in RCTs [9].”
Background
Metadata
- Authors
- Azoulay, L.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Azoulay, Laurent
- ORCID
- Azoulay, Laurent
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-06-28
- Volume
- 27
- Issue
- 9
- Pages
- e731-e738
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC9438907
- OpenAlex
- W4283693701
- Semantic Scholar
- be428d13a690826d0c488243ced0486f25cb7e18
- Cited by
- 79
- References
- 52
- Citations by year
- 2026: 24 · 2025: 28 · 2024: 15 · 2023: 11 · 2022: 1
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Oncologist (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Pfizer Canada
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- real-world evidence, oncology, randomized controlled trials, inclusion and exclusion criteria, cancer registry, drug approval, drug safety, effectiveness
- MeSH terms
- Canada, Humans, Medical Oncology, Neoplasms, Registries, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective. https://app.cochat.ai/papers/10.1093/oncolo/oyac114
- The paper
- Azoulay, L. (2022). Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective. The Oncologist. https://doi.org/10.1093/oncolo/oyac114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.